Director, Global Value and Health Economics and Outcomes Research

Jazz Pharmaceuticals•Philadelphia, PA

3d•$212,000 - $318,000•Remote

About The Position

The Director, Global Value and HEOR is a strategic and execution-oriented leadership role responsible for defining and driving global and US payer evidence strategy for pipeline assets from early clinical development (Phase 2/3) through regulatory approval and launch. The role leads global payer evidence generation while serving as the US HEOR lead for assigned assets, delivering pre-launch HEOR work, payer field tools, and US market access evidence strategies. It helps substantiate the value story developed by Market Access and translates target product profiles and access goals into evidence programs, including early economic models, natural history studies, Global Value Dossiers, and US AMCP dossiers. The Director works closely with Clinical Development to integrate payer, health plan, and HTA evidence needs into Phase 2 and pivotal Phase 3 study designs, including needs specific to rare diseases. In partnership with regional colleagues and the EU/INT HEOR team, the role develops HTA evidence strategies and analytical packages for European and other international assessments. The position combines strategic leadership with hands-on delivery and quality review of economic models, analyses, and dossier content. The Director leads HEOR launch-readiness workstreams, supports pre-launch observational research and real-world evidence, contributes to publications and congress presentations, and mentors junior scientists and matrix colleagues. The role collaborates across Clinical Development, Biostatistics, Market Access, Medical Affairs, Regulatory Affairs, Commercial, and regional HEOR teams.

Requirements

Master’s degree (MSc, MS, MPH, or PhD) in Health Economics, Outcomes Research, Pharmacoeconomics, or a closely related quantitative field.
7–10 years of experience in HEOR, Global Value, or Health Economics in the biopharmaceutical industry or a top-tier HEOR consulting firm.
Deep technical and conceptual expertise in health economic modeling, including Markov state-transition, partitioned survival, microsimulation, and decision-tree models.
Ability to build creative, defensible economic models in data-sparse pipeline and rare disease settings.
Experience working with Clinical Development, Commercial Development, and Biostatistics teams to influence Phase 2/3 trial design, comparator selection, resource-use collection, and PRO/HRQoL endpoints.
Familiarity with the US managed care and market access landscape, including commercial payers, Medicare Advantage, Medicare Part D/B, Medicaid, and PBMs, and understanding of global HTA frameworks such as EU HTA Regulation/JCA, NICE, G-BA, PBAC, and CADTH.
Ability to lead HEOR launch readiness, coordinate Day 1 access deliverables, and deliver GVDs, AMCP PIE dossiers, and global ITCs/NMAs under regulatory filing timelines.
In-depth knowledge of rare disease evidence challenges, including natural history studies, registries, surrogate endpoints, external control arms, and specialized HTA pathways.
Ability to set strategy while also executing and quality-checking technical models, statistical analysis plans, and dossier sections.
Demonstrated success collaborating with regional HEOR teams, particularly EU/INT teams, to co-develop HTA strategies.
Ability to influence cross-functional peers and senior leaders without formal authority.
Exceptional written and verbal communication skills and an established record of HEOR or clinical publications, or HTA success.
Direct experience leading HEOR strategy and deliverables for pipeline assets, including early Phase 2/3 trial integration, endpoint development, and global launch readiness.
Experience managing regional trade-offs in evidence needs during Phase 2/3 protocol development.
Launch lead experience for at least two assets as a US HEOR lead or country-level HTA lead.

Nice To Haves

Experience with neurology assets.
Above-country HEOR product leadership experience.
Experience serving as the US HEOR lead or delivering US pre-launch HEOR work such as AMCP PIE dossiers, US budget impact models, and payer field enablement, or significant exposure to these deliverables from a global role.
Direct experience in rare disease, orphan drug, or highly specialized pipeline programs.
Hands-on experience designing, overseeing, or adapting cost-effectiveness, budget impact, or early conceptual economic models.
Track record collaborating with regional HEOR teams, such as EU/INT teams, on evidence packages supporting HTA readiness and submissions.

Responsibilities

Partner with Clinical Development, Biostatistics, and Clinical Operations from Phase 2 planning through Phase 3 protocol freeze to incorporate global payer, US formulary, and HTA evidence requirements into trial designs.
Advocate for value-enhancing trial design elements, including relevant comparators, optimized eligibility criteria, appropriate treatment lines, and payer- and assessor-recognized endpoints.
Work with Patient-Centered Outcomes and Clinical teams to incorporate validated PROs, HRQoL measures, symptom burden scales, and HCRU instruments into pivotal trials.
Develop evidence strategies for rare disease assets using natural history data, disease progression biomarkers, and external or historical comparator cohorts to address clinical trial limitations.
Lead early-development health economic modeling strategies, including conceptual models, headroom and threshold analyses, cost-effectiveness analyses, and budget impact models.
Direct the design, construction, and validation of transparent global core economic models adaptable for international HTA dossiers and US payer contexts.
Serve as the US HEOR lead for assigned pipeline assets and develop and execute US pre-launch evidence generation plans with US Market Access and US Medical Affairs.
Lead development and completion of US AMCP PIE dossiers, unbranded burden-of-illness dossiers, and US budget impact models for commercial health plans, Medicare, and Medicaid audiences.
Partner with the US Payer Value and Outcomes team to develop compliant customer-facing economic models, evidence slide decks, and population health tools.
Plan for US policy and value assessment impacts, including ICER evaluations, the Inflation Reduction Act, and CMS price negotiations.
Lead HEOR workstreams within cross-functional Launch Readiness Teams and ensure evidence assets are validated, peer-reviewed, and ready for commercial and regulatory milestones.
Oversee development of Global Value Dossiers, systematic literature reviews, and early value communication tools.
Collaborate with EU/INT HEOR colleagues on HTA strategies and analytical packages, including indirect treatment comparisons, network meta-analyses, and country model adaptations for JCA, NICE, G-BA, CADTH, and other bodies.
Collaborate with RWE and epidemiology teams to design and execute pre-launch observational studies, chart reviews, disease registries, and burden-of-illness evaluations using US and international data.
Develop payer evidence strategies that substantiate, quantify, and defend the product value story developed by Market Access.
Participate as a core GVHEOR stakeholder in IEGP governance, prioritizing and coordinating HEOR and payer evidence needs, funding, and execution.
Serve as a HEOR authority and collaborator across Clinical Development, Market Access, Medical Affairs, Regulatory Affairs, and Commercial Brand teams.
Develop and execute pre-launch scientific publication plans, co-author peer-reviewed manuscripts, and present findings at congresses.
Mentor junior HEOR scientists, post-doctoral fellows, and matrix colleagues.